var singsData = [{"date":new Date(2012,1,21),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.123","showOnAxis":true},{"date":new Date(2012,1,21),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"UBS maintains IVZ to Buy. Target Price is $28; previously $25.","showOnAxis":false},{"date":new Date(2012,10,1),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"IVZ reports 2012 Q3's earning $0.42 per share and revenue $1040MM. This misses analyst's estimated EPS $0.45, misses estimated revenue $1060MM.","showOnAxis":false},{"date":new Date(2012,10,15),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.173","showOnAxis":true},{"date":new Date(2012,10,2),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Credit Suisse maintains IVZ to Outperform. Target Price is $27; previously $28.","showOnAxis":false},{"date":new Date(2012,10,2),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Nomura maintains IVZ to Buy. Target Price is $29; previously $28.","showOnAxis":false},{"date":new Date(2012,10,7),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Bank of America assumes IVZ to Buy. Target Price is $30.","showOnAxis":false},{"date":new Date(2012,2,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $30; previously $27.","showOnAxis":false},{"date":new Date(2012,3,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $26.","showOnAxis":false},{"date":new Date(2012,3,26),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2012 Q1's earning $0.43 per share and revenue $1033MM..","showOnAxis":false},{"date":new Date(2012,3,27),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Credit Suisse maintains IVZ to Outperform. Target Price is $32; previously $31.","showOnAxis":false},{"date":new Date(2012,3,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $26.","showOnAxis":false},{"date":new Date(2012,4,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $28.5; previously $31.","showOnAxis":false},{"date":new Date(2012,4,16),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.173","showOnAxis":true},{"date":new Date(2012,4,18),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"UBS maintains IVZ to Buy. Target Price is $28; previously $29.","showOnAxis":false},{"date":new Date(2012,5,21),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Argus Research initiates coverage on IVZ to Buy.","showOnAxis":false},{"date":new Date(2012,6,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Morgan Stanley maintains IVZ to Overweight. Target Price is $28; previously $29.","showOnAxis":false},{"date":new Date(2012,6,16),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $27; previously $28.","showOnAxis":false},{"date":new Date(2012,6,26),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2012 Q2's earning $0.41 per share and revenue $1010MM. This misses analyst's estimated EPS $0.43, misses estimated revenue $1040MM.","showOnAxis":false},{"date":new Date(2012,6,27),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"BMO Capital maintains IVZ to Outperform. Target Price is $26; previously $27.","showOnAxis":false},{"date":new Date(2012,6,27),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Morgan Stanley maintains IVZ to Overweight. Target Price is $29; previously $28.","showOnAxis":false},{"date":new Date(2012,6,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $26; previously $30.","showOnAxis":false},{"date":new Date(2012,7,20),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.173","showOnAxis":true},{"date":new Date(2012,7,20),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $27.5; previously $27.","showOnAxis":false},{"date":new Date(2012,7,24),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $29; previously $28.","showOnAxis":false},{"date":new Date(2012,8,13),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"UBS maintains IVZ to Buy. Target Price is $29; previously $28.","showOnAxis":false},{"date":new Date(2012,9,4),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $33; previously $27.5.","showOnAxis":false},{"date":new Date(2013,0,14),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"JP Morgan downgrades IVZ to Neutral from Overweight. Target Price is $31; previously $32.","showOnAxis":false},{"date":new Date(2013,0,31),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2012 Q4's earning $0.45 per share and revenue $1090MM. This misses analyst's estimated EPS $0.47, misses estimated revenue $1110MM.","showOnAxis":false},{"date":new Date(2013,1,1),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"Morgan Stanley downgrades IVZ to Equal-Weight from Overweight. Target Price is $30.","showOnAxis":false},{"date":new Date(2013,1,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Stifel Nicolaus maintains IVZ to Buy. Target Price is $30; previously $29.","showOnAxis":false},{"date":new Date(2013,1,19),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.172","showOnAxis":true},{"date":new Date(2013,1,5),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"BMO Capital downgrades IVZ to Market Perform from Outperform. Target Price is $29.","showOnAxis":false},{"date":new Date(2013,10,11),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"Wells Fargo upgrades IVZ to Outperform from Market Perform.","showOnAxis":false},{"date":new Date(2013,10,14),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"Goldman Sachs upgrades IVZ to Buy from Neutral. Target Price is $38; previously $35.","showOnAxis":false},{"date":new Date(2013,10,15),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.225","showOnAxis":true},{"date":new Date(2013,2,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Susquehanna initiates coverage on IVZ to Neutral. Target Price is $29.","showOnAxis":false},{"date":new Date(2013,3,12),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $35; previously $34.","showOnAxis":false},{"date":new Date(2013,3,23),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"JP Morgan upgrades IVZ to Overweight from Neutral. Target Price is $34; previously $31.","showOnAxis":false},{"date":new Date(2013,3,30),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2013 Q1's earning $0.52 per share and revenue $1142MM..","showOnAxis":false},{"date":new Date(2013,3,5),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $33; previously $31.","showOnAxis":false},{"date":new Date(2013,4,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Nomura maintains IVZ to Buy. Target Price is $35; previously $32.","showOnAxis":false},{"date":new Date(2013,4,13),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"UBS downgrades IVZ to Neutral from Buy.","showOnAxis":false},{"date":new Date(2013,4,15),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.225","showOnAxis":true},{"date":new Date(2013,4,15),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $38; previously $35.","showOnAxis":false},{"date":new Date(2013,4,2),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"Sterne Agee upgrades IVZ to Buy from Neutral. Target Price is $37; previously $33.","showOnAxis":false},{"date":new Date(2013,5,17),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $39; previously $37.","showOnAxis":false},{"date":new Date(2013,6,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Evercore Partners initiates coverage on IVZ to Equal-Weight. Target Price is $35.","showOnAxis":false},{"date":new Date(2013,6,25),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $36; previously $38.","showOnAxis":false},{"date":new Date(2013,7,19),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.225","showOnAxis":true},{"date":new Date(2013,9,16),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"JP Morgan downgrades IVZ to Neutral from Overweight. Target Price is $36; previously $41.","showOnAxis":false},{"date":new Date(2013,9,16),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Sterne Agee initiates coverage on IVZ to Neutral. Target Price is $33.","showOnAxis":false},{"date":new Date(2013,9,31),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2013 Q3's earning $0.55 per share and revenue $816.4MM. This beats analyst's estimated EPS $0.52, misses estimated revenue $1170MM.","showOnAxis":false},{"date":new Date(2014,0,31),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $44.","showOnAxis":false},{"date":new Date(2014,1,18),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.225","showOnAxis":true},{"date":new Date(2014,10,14),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.25","showOnAxis":true},{"date":new Date(2014,11,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Credit Suisse maintains IVZ to Outperform. Target Price is $45; previously $44.","showOnAxis":false},{"date":new Date(2014,11,4),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays initiates coverage on IVZ to Overweight. Target Price is $45.","showOnAxis":false},{"date":new Date(2014,11,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Market Perform. Target Price is $48; previously $45.","showOnAxis":false},{"date":new Date(2014,3,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $47; previously $48.","showOnAxis":false},{"date":new Date(2014,3,15),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Neutral. Target Price is $39; previously $38.","showOnAxis":false},{"date":new Date(2014,3,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $47; previously $48.","showOnAxis":false},{"date":new Date(2014,4,14),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.25","showOnAxis":true},{"date":new Date(2014,4,16),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank initiates coverage on IVZ to Hold. Target Price is $39.","showOnAxis":false},{"date":new Date(2014,4,2),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Neutral. Target Price is $41; previously $39.","showOnAxis":false},{"date":new Date(2014,4,2),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"UBS maintains IVZ to Neutral. Target Price is $37; previously $36.","showOnAxis":false},{"date":new Date(2014,4,20),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"JP Morgan upgrades IVZ to Overweight from Neutral. Target Price is $42; previously $41.","showOnAxis":false},{"date":new Date(2014,6,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $43; previously $42.","showOnAxis":false},{"date":new Date(2014,6,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $44; previously $40.","showOnAxis":false},{"date":new Date(2014,6,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Credit Suisse maintains IVZ to Outperform. Target Price is $44; previously $42.","showOnAxis":false},{"date":new Date(2014,7,1),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"Deutsche Bank upgrades IVZ to Buy from Hold. Target Price is $43; previously $39.","showOnAxis":false},{"date":new Date(2014,7,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $46; previously $45.","showOnAxis":false},{"date":new Date(2014,7,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"UBS maintains IVZ to Neutral. Target Price is $40; previously $37.","showOnAxis":false},{"date":new Date(2014,7,19),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.25","showOnAxis":true},{"date":new Date(2014,7,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Argus Research maintains IVZ to Buy. Target Price is $45; previously $42.","showOnAxis":false},{"date":new Date(2014,8,11),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $43.","showOnAxis":false},{"date":new Date(2014,9,14),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Bank of America maintains IVZ to Buy. Target Price is $43; previously $45.","showOnAxis":false},{"date":new Date(2014,9,14),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $46.","showOnAxis":false},{"date":new Date(2014,9,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $45; previously $46.","showOnAxis":false},{"date":new Date(2015,0,26),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"Susquehanna upgrades IVZ to Positive from Neutral.","showOnAxis":false},{"date":new Date(2015,0,30),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $50.","showOnAxis":false},{"date":new Date(2015,0,6),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"Credit Suisse downgrades IVZ to Neutral from Outperform. Target Price is $45.","showOnAxis":false},{"date":new Date(2015,0,7),"type":"arrowUp","text":null,"backgroundColor":"#00CC00","graph":"g1","description":"Sterne Agee upgrades IVZ to Buy from Neutral. Target Price is $47; previously $45.","showOnAxis":false},{"date":new Date(2015,0,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $47; previously $48.","showOnAxis":false},{"date":new Date(2015,1,17),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.25","showOnAxis":true},{"date":new Date(2015,10,13),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.27","showOnAxis":true},{"date":new Date(2015,11,16),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $39; previously $43.","showOnAxis":false},{"date":new Date(2015,2,5),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $46; previously $44.","showOnAxis":false},{"date":new Date(2015,2,5),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Market Perform. Target Price is $52; previously $47.","showOnAxis":false},{"date":new Date(2015,2,6),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $44.","showOnAxis":false},{"date":new Date(2015,3,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $47; previously $45.","showOnAxis":false},{"date":new Date(2015,3,13),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $44.","showOnAxis":false},{"date":new Date(2015,3,2),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $45.","showOnAxis":false},{"date":new Date(2015,3,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $51; previously $52.","showOnAxis":false},{"date":new Date(2015,4,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $52; previously $51.","showOnAxis":false},{"date":new Date(2015,4,13),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.27","showOnAxis":true},{"date":new Date(2015,5,3),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"PiperJaffray initiates coverage on IVZ to Overweight. Target Price is $50.","showOnAxis":false},{"date":new Date(2015,5,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Goldman Sachs initiates coverage on IVZ to Neutral. Target Price is $44.","showOnAxis":false},{"date":new Date(2015,6,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $44; previously $47.","showOnAxis":false},{"date":new Date(2015,6,14),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Credit Suisse maintains IVZ to Neutral. Target Price is $46; previously $48.","showOnAxis":false},{"date":new Date(2015,6,20),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $43.","showOnAxis":false},{"date":new Date(2015,6,31),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $45; previously $44.","showOnAxis":false},{"date":new Date(2015,6,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Susquehanna maintains IVZ to Positive. Target Price is $44; previously $48.","showOnAxis":false},{"date":new Date(2015,7,18),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.27","showOnAxis":true},{"date":new Date(2015,8,10),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $51.","showOnAxis":false},{"date":new Date(2015,8,3),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $43; previously $49.","showOnAxis":false},{"date":new Date(2015,8,3),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Susquehanna maintains IVZ to Positive. Target Price is $39; previously $45.","showOnAxis":false},{"date":new Date(2015,8,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $40; previously $45.","showOnAxis":false},{"date":new Date(2015,9,7),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $39; previously $46.","showOnAxis":false},{"date":new Date(2015,9,8),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $39; previously $41.","showOnAxis":false},{"date":new Date(2016,0,11),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $40; previously $41.","showOnAxis":false},{"date":new Date(2016,0,19),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $33; previously $36.","showOnAxis":false},{"date":new Date(2016,1,16),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.27","showOnAxis":true},{"date":new Date(2016,1,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $32; previously $35.","showOnAxis":false},{"date":new Date(2016,1,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $32; previously $34.","showOnAxis":false},{"date":new Date(2016,1,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $36; previously $39.","showOnAxis":false},{"date":new Date(2016,10,10),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.28","showOnAxis":true},{"date":new Date(2016,11,13),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"Keefe Bruyette & Woods downgrades IVZ to Market Perform from Outperform.","showOnAxis":false},{"date":new Date(2016,2,17),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $33.","showOnAxis":false},{"date":new Date(2016,3,1),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $32.","showOnAxis":false},{"date":new Date(2016,3,28),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2016 Q1's earning $0.49 per share and revenue $818.1MM. This misses analyst's estimated EPS $0.54, misses estimated revenue $855.66MM.","showOnAxis":false},{"date":new Date(2016,3,5),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $36; previously $34.","showOnAxis":false},{"date":new Date(2016,3,7),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $39; previously $36.","showOnAxis":false},{"date":new Date(2016,4,11),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.28","showOnAxis":true},{"date":new Date(2016,5,16),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $35.","showOnAxis":false},{"date":new Date(2016,5,2),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"UBS downgrades IVZ to Neutral from Buy.","showOnAxis":false},{"date":new Date(2016,5,27),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"Citigroup downgrades IVZ to Neutral from Buy. Target Price is $27; previously $38.","showOnAxis":false},{"date":new Date(2016,6,11),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $35.","showOnAxis":false},{"date":new Date(2016,6,18),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $33; previously $32.","showOnAxis":false},{"date":new Date(2016,6,28),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2016 Q2's earning $0.56 per share and revenue $856.6MM. This beats analyst's estimated EPS $0.55, beats estimated revenue $848.82MM.","showOnAxis":false},{"date":new Date(2016,6,29),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $34.","showOnAxis":false},{"date":new Date(2016,6,29),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Neutral. Target Price is $31; previously $27.","showOnAxis":false},{"date":new Date(2016,6,29),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"JP Morgan maintains IVZ to Overweight. Target Price is $37; previously $36.","showOnAxis":false},{"date":new Date(2016,6,29),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $34; previously $33.","showOnAxis":false},{"date":new Date(2016,6,7),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $37.","showOnAxis":false},{"date":new Date(2016,7,16),"type":"sign","text":"D","backgroundColor":"#ADD8E6","graph":"g1","description":"The Firm pays dividend $0.28","showOnAxis":true},{"date":new Date(2016,7,5),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $33.","showOnAxis":false},{"date":new Date(2016,7,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight. Target Price is $36; previously $35.","showOnAxis":false},{"date":new Date(2016,8,9),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $35; previously $34.","showOnAxis":false},{"date":new Date(2016,9,11),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Jefferies maintains IVZ to Buy.","showOnAxis":false},{"date":new Date(2016,9,13),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Barclays maintains IVZ to Overweight.","showOnAxis":false},{"date":new Date(2016,9,14),"type":"arrowDown","text":null,"backgroundColor":"#CC0000","graph":"g1","description":"Deutsche Bank downgrades IVZ to Hold from Buy.","showOnAxis":false},{"date":new Date(2016,9,14),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Keefe Bruyette & Woods maintains IVZ to Outperform.","showOnAxis":false},{"date":new Date(2016,9,27),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2016 Q3's earning $0.6 per share and revenue $854.7MM. This meets analyst's estimated EPS $0.6, misses estimated revenue $863.53MM.","showOnAxis":false},{"date":new Date(2016,9,4),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Citigroup maintains IVZ to Neutral. Target Price is $33; previously $31.","showOnAxis":false},{"date":new Date(2016,9,5),"type":"sign","text":"R","backgroundColor":"#ADE6C4","graph":"g1","description":"Deutsche Bank maintains IVZ to Buy. Target Price is $36; previously $35.","showOnAxis":false},{"date":new Date(2017,0,26),"type":"sign","text":"E","backgroundColor":"#FFFF00","graph":"g1","description":"Before market open, IVZ reports 2016 Q4's earning $0.59 per share and revenue $863.8MM. This beats analyst's estimated EPS $0.58, beats estimated revenue $862.89MM.","showOnAxis":false}];